Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedegund Meier

Showing results (31-40 of 234) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibitionTeresa Amaral, Tobias Sinnberg, Friedegund Meier, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 2, 2019
Sources of information and support for melanoma patients: differences between patients' and clinicians' preferencesJulia Brütting, Maike Bergmann, Dirk Schadendorf, et al.
Pharmacological Research|August 27, 2018
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapyMarvin Kuske, Dana Westphal, Rebekka Wehner, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 27, 2019
Informations- und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und ÄrztenJulia Brütting, Maike Bergmann, Dirk Schadendorf, et al.
Oncogene|October 10, 2003
Reciprocal regulation of MelCAM and AKT in human melanomaGang Li, Jiri Kalabis, Xiaowei Xu, et al.
Biomedicines|March 2, 2018
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor TreatmentAntje Tunger, Maximilian Kießler, Rebekka Wehner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2017
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibitionTeresa Amaral, Tobias Sinnberg, Friedegund Meier, et al.
Melanoma Research|March 11, 2010
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?Ulrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Dermatology (Basel, Switzerland)|November 6, 2023
Clinician's Ability to Identify Non-Melanoma Skin Cancer on 3D-Total Body Photography Sectors that Were Initially Identified during In-Person Skin Examination with DermoscopySarah Hobelsberger, Julian Steininger, Jörg Laske, et al.
Cancer Biology & Therapy|December 20, 2013
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibitionMahmoud Toulany, Minjmaa Minjgee, Mohammad Saki, et al.
Pageof 24

Showing results (31-40 of 234) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibitionTeresa Amaral, Tobias Sinnberg, Friedegund Meier, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 2, 2019
Sources of information and support for melanoma patients: differences between patients' and clinicians' preferencesJulia Brütting, Maike Bergmann, Dirk Schadendorf, et al.
Pharmacological Research|August 27, 2018
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapyMarvin Kuske, Dana Westphal, Rebekka Wehner, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 27, 2019
Informations- und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und ÄrztenJulia Brütting, Maike Bergmann, Dirk Schadendorf, et al.
Oncogene|October 10, 2003
Reciprocal regulation of MelCAM and AKT in human melanomaGang Li, Jiri Kalabis, Xiaowei Xu, et al.
Biomedicines|March 2, 2018
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor TreatmentAntje Tunger, Maximilian Kießler, Rebekka Wehner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2017
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibitionTeresa Amaral, Tobias Sinnberg, Friedegund Meier, et al.
Melanoma Research|March 11, 2010
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?Ulrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Dermatology (Basel, Switzerland)|November 6, 2023
Clinician's Ability to Identify Non-Melanoma Skin Cancer on 3D-Total Body Photography Sectors that Were Initially Identified during In-Person Skin Examination with DermoscopySarah Hobelsberger, Julian Steininger, Jörg Laske, et al.
Cancer Biology & Therapy|December 20, 2013
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibitionMahmoud Toulany, Minjmaa Minjgee, Mohammad Saki, et al.
Pageof 24